Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

RAPT Therapeutics, Inc. - Common Stock (NQ:RAPT)

8.460 -0.160 (-1.86%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about RAPT Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Reports Second Quarter 2023 Financial Results
Company maintains strong cash position of $205 million 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Reports First Quarter 2023 Financial Results
Company maintains strong cash position of $231.6 million 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results
Company maintains strong cash position of $249.1 million 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics to Participate in the SVB Securities Global Biopharma Conference
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer
Data Presented at ESMO Immuno-Oncology Congress 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Reports Third Quarter 2022 Financial Results
Company maintains strong cash position of $195.4 million 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Strengthens Leadership Team with Two New Key Hires
From RAPT Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.